PRKCB and B-cell chronic lymphocytic leukemia: Both BTKY551 and BTKY223 phosphorylation levels were significantly downregulated upon PKCβ inhibition with Enza in human CLL cells compared to NDC, while IB treatment led to a significant downregulation of BTKY223 phosphorylation only (Figure 6A).